Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.42 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.42 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531352 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2527437 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2480183 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2533103 | 0.85 | SMN1; SMN2 (0.66) | SMN1; SMN2TSHRALDH1A1LMNAMAPT | |
| SCHEMBL2527092 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL3919987 | 0.85 | ADRB2 (0.51) | SMN1; SMN2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL2560835 | 0.83 | AR (0.47) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2525286 | 0.82 | CYP3A4 (0.47) | SMN1; SMN2TSHRARALDH1A1LMNA | |
| SCHEMBL2526160 | 0.82 | AR (0.51) | SMN1; SMN2TSHRARALDH1A1MAPT | |
| SCHEMBL2528462 | 0.82 | MAPT (0.49) | SMN1; SMN2TSHRALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102858742-B | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2015-05-27 | — | — | CN | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| CN-103382176-A | Novel vanilloid receptor ligands and their use for producing medicaments | GRUENENTHAL GMBH | 2013-11-06 | — | — | CN | disclosed |
| CN-101331124-B | Novel capsaicin receptor ligands and their use for the manufacture of medicaments | GRUENENTHAL GMBH | 2013-08-14 | — | — | CN | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-1940821-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | GENFIT (FR) | 2006-04-13 | — | — | US | disclosed |
| WO-2006035157-A2 | SUBSTITUTED N-(BENZYL)PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME AS PPAR LIGANDS IN THE TREATMENT OF LIPID AND/OR GLUCIDIC DISORDERS | GENFIT (FR) | 2006-04-06 | — | — | WO | disclosed |
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | AADAC, NAT1, PARN | SMN1; SMN2 1048/4885TSHR 4628/4885AR 3040/4885 |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | SMN1; SMN2 4541/4885TSHR 969/4885AR 1239/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | SMN1; SMN2 4541/4885TSHR 969/4885AR 1239/4885 |
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | SMN1; SMN2 1836/4885TSHR 859/4885AR 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.